Novartis, Abbott New R&D Models Focus On Translational Medicine
Translational medicine will assist companies with targeting the right indication for a compound, a Novartis representative said at IBC's Drug Discovery Technology & Development conference Aug. 8 in Boston
You may also be interested in...
Novartis is advocating a two-phase drug development paradigm based on "models of disease.
Manufacturers and laboratories producing investigational new drugs in Phase I studies are exempt from having to fully validate their manufacturing process under new FDA guidelines
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011